In patients suffering from dehydration and renal disease, particularly the elderly, concurrent therapy with other plasma protein binding drugs may decessitate a modification in dosage. In the case of anticoagulants, the dose of the anticoagulant may need to be reduced. The safety of Mefenamic Acid in pregnancy and in children under 14 years of age has not been established.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign Out
